• Articles
• Presentations
• Events/Seminars
• IP Alerts
• Q&A Booklets
• In the News
• Press Releases
• IP Case Law Analysis
• IP Outlook Newsletter
• RSS Feeds

Salix's polymorph patents for Xifaxan may be vulnerable to future challenge, experts say

Hunter Baker was quoted in an article in Pharmawire on Salix Pharmaceuticals’ patent portfolio.